Anti-amyloid therapy crossover — the monoclonal antibodies (lecanemab, donanemab) and BACE inhibitors originally developed for Alzheimer's disease (AD) demonstrating mechanistic relevance to cerebral amyloid angiopathy (CAA) pathophysiology — creating the most promising therapeutic pipeline expansion in CAA treatment, with the Cerebral Amyloid Angiopathy Treatment Market tracking...